🏆 Deal of the Month · February 2022
SpliceBio raised EUR 50 million in an oversubscribed Series A financing round, with valuation remaining undisclosed. The round closed in February 2022 and was recognised as Venionaire DealMatrix Deal of the Month for that period. Six specialist life-science investors participated, with Asabys Partners and Gilde Healthcare joined by New Enterprise Associates, Novartis Venture Fund, UCB Ventures, and Ysios Capital.
SpliceBio — key deal facts
| Company | SpliceBio |
| Founded | 2012 |
| Headquarters | Barcelona, Spain |
| Amount raised | EUR 50M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series A |
| Investors | Asabys Partners (https://asabys.com/) Gilde Healthcare (https://gildehealthcare.com/) New Enterprise Associates (https://www.nea.com/) Novartis Venture Fund (https://www.nvfund.com/) UCB Ventures (https://www.ucbventures.com/) Ysios Capital (https://ysioscapital.com/) |
| Sectors | Biotechnology |
Who invested in SpliceBio?
The syndicate spans European specialist funds and US growth-stage venture capital alongside corporate strategic investors. Asabys Partners and Ysios Capital bring deep Spanish and pan-European biotech networks, while New Enterprise Associates adds US venture scale. Novartis Venture Fund and UCB Ventures represent strategic pharmaceutical interest in the genetic medicines space, underscoring the platform's perceived clinical relevance.
What does SpliceBio do?
SpliceBio is a clinical-stage genetic medicines company founded in 2012 and headquartered in Barcelona, Spain, within the Parc Científic de Barcelona technology cluster. The company has developed a proprietary Protein Splicing platform designed to deliver gene therapies for diseases caused by mutations in large genes — a segment historically underserved by conventional single adeno-associated viral (AAV) vector approaches. Its lead programme, SB-007, is a dual-AAV gene therapy targeting Stargardt disease and is the first such construct cleared by the FDA for clinical development in that indication. The company was co-founded by Miquel Vila-Perelló, Ph.D., drawing on protein splicing technology developed over two decades at the Muir Lab, Princeton University.
SpliceBio valuation & multiples
Explore the benchmarks: Series A.
Frequently asked questions
How much did SpliceBio raise in its Series A?
SpliceBio raised EUR 50 million in an oversubscribed Series A round that closed in February 2022.
What is SpliceBio's valuation?
SpliceBio's valuation was not disclosed in connection with its Series A financing.
Who invested in SpliceBio?
The Series A was backed by Asabys Partners, Gilde Healthcare, New Enterprise Associates, Novartis Venture Fund, UCB Ventures, and Ysios Capital.
When was SpliceBio founded and where is it based?
SpliceBio was founded in 2012 and is headquartered in Barcelona, Spain.
Source: original announcement — read the full report.